Type your tag names separated by a space and hit enter
Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
OBJECTIVETo assess the incidence of endometrial polyps during postmenopausal replacement therapy with tibolone, using an appropriate control group.
DESIGNA total of 485 postmenopausal women were included in this open, prospective, comparative study for a duration of 36 months. Of this group, 249 women received 2.5 mg/day of tibolone and 244 women served as controls, receiving continuous-combined estrogen-progestogen therapy (HT). Transvaginal ultrasound, hysteroscopy, and directed biopsies were performed before treatment was initiated and at the end of the study.
RESULTSTwo hundred twenty-one of the women receiving tibolone and 203 receiving continuous-combined HT completed the study. Endometrial polyps were detected in 74 women (33.4%) from the tibolone group and in 22 women (10.8%) from the HT group (P < 0.01). The vaginal bleeding rate did not differ between the groups. The frequency of atrophic polyps was significantly higher in the tibolone group (P < 0.01). No difference was found in the size of the polyps.
CONCLUSIONSTibolone increases by threefold the risk for endometrial polyps.
Santa Cristina University Hospital, Universidad Autónoma de Madrid, Madrid, Spain. firstname.lastname@example.org, , , , ,
Menopause (New York, N.Y.) 10:6 pg 534-7
Estrogen Receptor Modulators
Estrogen Replacement Therapy
Pub Type(s)Comparative Study